Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 21

Cat.No. Product Name Information/Activity
BCC7407 GYKI 53655 hydrochloride GYKI53655 hydrochloride is an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonist.
BCC7275 NS 3763 70553-45-6
BCC6378 Talampanel(LY300164) Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED).
BCC2314 Topiramate Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
BCC7171 UBP 282 544697-47-4
BCC7255 UBP 296 745055-86-1
BCC7172 UBP 301 569371-10-4
BCC7256 UBP 302 UBP 302 is a potent and selective GLUK5-subunit containing kainate receptor antagonist (apparent Kd=402 nM), and displays very little affinity on GluK2 (GluR6) kainate receptors. Anxiolytic effects.
BCC6052 UBP 310 902464-46-4
BCC7339 ZK 200775 Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.